Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: An 11-year follow-up study

HIV Medicine

Volumn 5, Issue 6, 2004, Pages 431-436

  Manfredi, Roberto ^a   Nanetti, A ^a   Valentini, R ^a   Ferri, M ^a   Morelli, S ^a   Calza, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antimicrobial resistance; Antiretroviral therapy; Clinical features; Epidemiology; HIV infection; Mycobacterium kansasii

Indexed keywords

AMINOSALICYLIC ACID; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CAPREOMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PROTIONAMIDE; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; CULTURE TECHNIQUE; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM KANSASII; NONHUMAN; OPPORTUNISTIC INFECTION; PREDICTION; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII; RETROSPECTIVE STUDIES;

EID: 9244224084     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00249.x     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Manfredi R, Calza L, Chiodo F. Lack of change in the distribution of AIDS-defining opportunistic diseases and the related degree of immunodeficiency during the periods before and after the introduction of highly active antiretroviral, therapy. Eur J Clin Microbiol Infect Dis 2001; 20: 410-413.
3. Klein JL, Corbett EL, Slade PM, Miller RF, Coker RJ. Mycobacterium kansasii and human immunodeficiency virus co-infection in London. J Infect 1998; 37: 252-259.
4. Yamada H, Kohyama T, Terashi K et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium kansasii which developed in an immunocompetent young man. Intern Med 1997; 36 298-300.
5. Bernard L, Vincent V, Lortholary O et al. Mycobacterium kansasii septic arthritis. French retrospective study of 5 years and review. Clin Infect Dis 1999; 29: 1455-1460.
6. Block KC, Zwerling L, Pletcher MJ et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129: 698-704.
7. Lortholary O, Deniel F, Boudon P et al. Mycobacterium kansasii infection in a Paris suburb: comparison of disease presentation and outcome according to human immunodeficiency virus status. Int J Tuberculosis Lung Dis 1999; 3: 68-73.
8. Corbett EL, Churchyard GJ, Hay M et al. The impact of HIV infection on Mycobacterium kansasii disease in South African gold miners. Am J Respir Care Med 1999; 160: 10-14.
9. Pintado V, Fortun J, Casado JL, Gomez-Mampaso E. Mycobacterium kansasii pericarditis as a presentation of AIDS. Infection 2001; 29: 48-50.
10. National Centres for Clinical and Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement, Vol. 22. Philadelphia, PA, USA, National Centres for Clinical and Laboratory Standards, 2002.
11. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 1209-1215.
12. Patel S, Wolf T. Cavitary lung lesions due to coinfection of Rhodococcus equi and Mycobacterium kansasii in a patient with acquired immunodeficiency syndrome. Am J Med 2002; 112: 678-680.
13. Burckhard B, Sendi P, Pfluger D et al. Rare AIDS-defining diseases in the Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1999; 18: 399-402.
14. Pintado V, Gomez-Mampaso E, Martin-Davila P et al. Mycobacterium kansasii infection in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1999; 18 582-586.
15. Sullivan AK, Hannan MM, Azadian BS, Easterbrook PJ, Gazzard BG, Nelson MR. Acid-alcohol fast bacilli in sputa of HIV-infected patients. Int J STD AIDS 1999; 10: 606-608.
16. Witzig RS, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother 1993; 37: 1997-1999.
17. Raynaud C, Laneelle MA, Senaratne RH, Draper P, Laneelle G, Daffe M. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999; 145: 1359-1367.
18. Ho H, Chan CY, Cheng AF. Aminoglycoside resistance in Mycobacterium kansasii, Mycobacterium avium-M. intracellulare, and Mycobacterium fortuitum: are aminoglycoside-modifying enzymes responsible? Antimicrob Agents Chemother 2000; 44: 39-42.
19. Graybill JR, Bocanegra R. Treatment alternatives for Mycobacterium kansasii. J Antimicrob Chemother 2001; 47: 417-420.
20. Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 1999; 43: 537-542.
21. Burman WJ, Stone BL, Brown BA, Wallace RJ Jr, Bottger EC. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. Diagn Microbiol Infect Dis 1998; 31: 369-371.